Table 1.
Indexes for the prediction of liver steatosis
| Index | Author(nation) | Paper (yr) | No. of subjects(fatty liver/ non-fatty liver) | Parameters | Cutoff values | Sens-itivity | Speci-ficity | AUROC | Diagnostic methods for hepatic steatosis |
| FLI | Bedogni(Italy) | BMC Gastroenterology (2006) | 228/268 | BMI, waist circumference, triglyceride, γGT | < 30 > 60 | 87.0%61.0% | 64.0%86.0% | 0.84 | US |
| NAFLD liver fat score1 | Kontronen(Finland) | Gastroenterology (2009) | 470 | MetS, type II diabetes, IRI, AST, AST/ALT ratio | -0.64 | 86.0% | 71.0% | 0.8720.863 | MRS |
| HSI | Lee (South Korea) | Dig Liver Dis (2010) | 5362/5362 (sex- and age- matched) | 8 × AST/ALT ratio + BMI + (+ 2 for females, + 2 for diabetes) | < 30 > 36 | 93.1% | 92.4% | 0.812 | US |
| ST | Poynaud(France) | Comp Hepatol(2005) | 744/140 | 12 parameters4 | 0.30 0.72 | 90% | 90.0% | 0.7920.8030.8630.723 | Biopsy |
| Park (South Korea) | Korean J Hepatol(2011) | 145/311 | ALT/AST > 1.5 (= 1 point)γGT > 50 IU/L (= 1 point)TG > 150 mg/dL (= 1 point)BMI 23-24.9 (= 2 points) ≥ 25 (= 3 points) | 3 | 71.7% | 75.9% | 0.797 | US | |
| Bajaj(India) | Indian J Med Res (2009) | 39/82 | IRI +1.6 × BMI + 1.9 × FPG | 1.6 | 84.6% | 76.0% | 0.76 | US |
1
PNPLA3 did not improve diagnostic accuracies;
2
Estimation group;
3
Validation group;
4
Alanine aminotransferase (ALT), α2-macroglobulin, apolipoprotein A-I, haptoglobin, total bilirubin, γ-glutamyl transferase (γGT), cholesterol, triglycerides, glucose, age, gender and body mass index (BMI). ROC: Receiver operating characteristics curve; US: Ultrasonography; MetS: Metabolic syndrome; MRS: Magnetic resonance spectroscopy, IRI: Immuno-reactive insulin; FPG: Fasting plasma glucose. FLI: Fatty liver index; HSI: Hepatic steatosis index; ST: Steato Test; AST: Aspartate aminotransferase; NAFLD: Nonalcoholic fatty liver disease; AUROC: Area under the receiver operating characteristic curve.